PCSK9 Inhibitors - Alirocumab and Evolucumab: Key Insights on Differentiation in a Generic Market

Value in Health - United Kingdom
doi 10.1016/j.jval.2016.03.152
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV